CA2690865A1 - Methods of diagnosing and treating cancer - Google Patents
Methods of diagnosing and treating cancer Download PDFInfo
- Publication number
- CA2690865A1 CA2690865A1 CA2690865A CA2690865A CA2690865A1 CA 2690865 A1 CA2690865 A1 CA 2690865A1 CA 2690865 A CA2690865 A CA 2690865A CA 2690865 A CA2690865 A CA 2690865A CA 2690865 A1 CA2690865 A1 CA 2690865A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- rrm1
- level
- expression
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 title claims description 32
- 201000011510 cancer Diseases 0.000 title claims description 13
- 230000014509 gene expression Effects 0.000 claims abstract description 34
- 108010022394 Threonine synthase Proteins 0.000 claims abstract 22
- 102000005497 Thymidylate Synthase Human genes 0.000 claims abstract 22
- 230000001086 cytosolic effect Effects 0.000 claims abstract 7
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims abstract 3
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims abstract 3
- 238000004393 prognosis Methods 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 101150118217 RRM1 gene Proteins 0.000 claims 1
- 101150112897 TS gene Proteins 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000010249 in-situ analysis Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000164466 Palaemon adspersus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 101150067539 AMBP gene Proteins 0.000 description 1
- 101150026006 ASP1 gene Proteins 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 101100536691 Bacillus subtilis (strain 168) tenI gene Proteins 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101150026868 CHS1 gene Proteins 0.000 description 1
- 101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100440695 Dictyostelium discoideum corB gene Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 101150066318 GRC3 gene Proteins 0.000 description 1
- 102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 1
- 101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 1
- 101000643895 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 6 Proteins 0.000 description 1
- 241000917703 Leia Species 0.000 description 1
- 101150076419 MT-CO3 gene Proteins 0.000 description 1
- 244000131360 Morinda citrifolia Species 0.000 description 1
- 101100322023 Mus musculus Ablim1 gene Proteins 0.000 description 1
- 101100448410 Mus musculus Gkn1 gene Proteins 0.000 description 1
- 101100479616 Mus musculus Iars1 gene Proteins 0.000 description 1
- 101100514359 Mus musculus Mrtfa gene Proteins 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 101150093297 NAD4 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000644027 Perideridia lemmonii Species 0.000 description 1
- 101150005409 Pmch gene Proteins 0.000 description 1
- 241000549435 Pria Species 0.000 description 1
- 241001430696 Protis Species 0.000 description 1
- 101100061105 Rattus norvegicus Mtco3 gene Proteins 0.000 description 1
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
- 101100042848 Rattus norvegicus Smok gene Proteins 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 101100006923 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cnd1 gene Proteins 0.000 description 1
- 101100392422 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ght3 gene Proteins 0.000 description 1
- 101100408822 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pom1 gene Proteins 0.000 description 1
- 101100022918 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sua1 gene Proteins 0.000 description 1
- 241001500335 Scina Species 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 101100453510 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) katG gene Proteins 0.000 description 1
- 101100263415 Streptomyces hygroscopicus subsp. jinggangensis (strain 5008) valL gene Proteins 0.000 description 1
- 241000724822 Teia Species 0.000 description 1
- 101100309642 Thiobacillus thioparus scnC gene Proteins 0.000 description 1
- 241001130469 Tila Species 0.000 description 1
- 102100021015 Ubiquitin carboxyl-terminal hydrolase 6 Human genes 0.000 description 1
- 101000870345 Vasconcellea cundinamarcensis Cysteine proteinase 1 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000015107 ale Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 101150071300 catC gene Proteins 0.000 description 1
- 101150112018 ced-4 gene Proteins 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 101150111011 ficd gene Proteins 0.000 description 1
- 101150106199 fliL gene Proteins 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 101150111658 katE gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- BWXAXMBARINVRN-UHFFFAOYSA-N methyl 2-(7-methyl-3-phenylindazol-1-yl)acetate Chemical compound C12=CC=CC(C)=C2N(CC(=O)OC)N=C1C1=CC=CC=C1 BWXAXMBARINVRN-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- SYDXFYIGIIAPLB-OKRPGNDBSA-N ntii Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC(=C3NC=25)N=C=S)O)CC1)O)CC1CC1 SYDXFYIGIIAPLB-OKRPGNDBSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 101150039516 ple3 gene Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 102220013976 rs45476991 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94415707P | 2007-06-15 | 2007-06-15 | |
| US60/944,157 | 2007-06-15 | ||
| US3955508P | 2008-03-26 | 2008-03-26 | |
| US61/039,555 | 2008-03-26 | ||
| PCT/US2008/066918 WO2008157353A1 (en) | 2007-06-15 | 2008-06-13 | Methods of diagnosing and treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2690865A1 true CA2690865A1 (en) | 2008-12-24 |
Family
ID=40156627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2690865A Abandoned CA2690865A1 (en) | 2007-06-15 | 2008-06-13 | Methods of diagnosing and treating cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090017012A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2171086B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5479332B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100044780A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101815793A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008266048A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0813364A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2690865A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2401475T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009013646A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2010101093A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008157353A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1877569A4 (en) * | 2005-05-04 | 2009-07-15 | Univ South Florida | PREDICTING THE RESPONSE TO TREATMENT OF CANCER PATIENTS |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| BRPI0711011A2 (pt) | 2006-05-18 | 2011-08-23 | Molecular Profiling Institute, Inc. | método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença |
| EP2730662A1 (en) * | 2008-11-12 | 2014-05-14 | Caris Life Sciences Luxembourg Holdings | Methods and systems of using exosomes for determining phenotypes |
| WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
| JP5024736B2 (ja) | 2009-10-15 | 2012-09-12 | 住友電気工業株式会社 | 発電システム |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| US10660965B2 (en) | 2010-03-29 | 2020-05-26 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| KR101602532B1 (ko) * | 2013-08-29 | 2016-03-11 | 경북대학교 산학협력단 | 위암의 재발 가능성 예측을 위한 정보제공 방법 |
| US20180312928A1 (en) * | 2015-10-26 | 2018-11-01 | Cipherome | Method and system for selecting customized drug using genomic nucleotide sequence variation information and survival information of cancer patient |
| AU2021305654A1 (en) * | 2020-07-10 | 2023-03-02 | Progenics Pharmaceuticals, Inc | Methods of making prostate cancer treatment decisions |
| CN113957145B (zh) * | 2021-10-19 | 2023-09-26 | 中国医学科学院肿瘤医院 | m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用 |
| CN114564622B (zh) * | 2022-03-03 | 2025-07-25 | 苏州良医汇网络科技有限公司 | 一种tnm分期表录入系统的方法、装置以及设备 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705336A (en) * | 1995-03-07 | 1998-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Assay for sensitivity of tumors to DNA-platinating chemotherapy |
| US20020090642A1 (en) * | 1995-12-11 | 2002-07-11 | Patrick G. Johnston | Methods for determining the prognosis of breast cancer using antibodies specific for thymidylate synthase |
| WO1998033518A1 (en) * | 1997-02-04 | 1998-08-06 | Sloan-Kettering Institute For Cancer Research | Mutants of thymidylate synthase and uses thereof |
| US6087489A (en) * | 1998-06-02 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of human thymidylate synthase expression |
| AU5569600A (en) * | 1999-06-28 | 2001-01-31 | Yusuke Nakamura | Novel protein and dna thereof |
| US6248535B1 (en) * | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
| US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| US6518416B1 (en) * | 2000-12-01 | 2003-02-11 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| US7049059B2 (en) * | 2000-12-01 | 2006-05-23 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
| US6582919B2 (en) * | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
| US6956111B2 (en) * | 2001-03-02 | 2005-10-18 | Response Genetics, Inc. | Method of determining dihydropyrimidine dehydrogenase gene expression |
| US6686155B2 (en) * | 2001-06-14 | 2004-02-03 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression |
| US7919235B2 (en) * | 2002-09-30 | 2011-04-05 | F. Hoffman-La Roche Ag | Oligonucleotides for genotyping thymidylate synthase gene |
| JP2007507770A (ja) * | 2003-09-29 | 2007-03-29 | パスワーク インフォーマティクス，インコーポレーテッド | 生物学的特徴を検出するためのシステムおよび方法 |
| EP1877569A4 (en) * | 2005-05-04 | 2009-07-15 | Univ South Florida | PREDICTING THE RESPONSE TO TREATMENT OF CANCER PATIENTS |
-
2008
- 2008-06-13 KR KR1020107000955A patent/KR20100044780A/ko not_active Withdrawn
- 2008-06-13 BR BRPI0813364-6A2A patent/BRPI0813364A2/pt not_active IP Right Cessation
- 2008-06-13 RU RU2010101093/10A patent/RU2010101093A/ru not_active Application Discontinuation
- 2008-06-13 EP EP08771019A patent/EP2171086B1/en not_active Not-in-force
- 2008-06-13 MX MX2009013646A patent/MX2009013646A/es not_active Application Discontinuation
- 2008-06-13 WO PCT/US2008/066918 patent/WO2008157353A1/en not_active Ceased
- 2008-06-13 US US12/139,134 patent/US20090017012A1/en not_active Abandoned
- 2008-06-13 JP JP2010512384A patent/JP5479332B2/ja not_active Expired - Fee Related
- 2008-06-13 CN CN200880102571A patent/CN101815793A/zh active Pending
- 2008-06-13 ES ES08771019T patent/ES2401475T3/es active Active
- 2008-06-13 CA CA2690865A patent/CA2690865A1/en not_active Abandoned
- 2008-06-13 AU AU2008266048A patent/AU2008266048A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100044780A (ko) | 2010-04-30 |
| ES2401475T3 (es) | 2013-04-19 |
| AU2008266048A1 (en) | 2008-12-24 |
| JP2010530746A (ja) | 2010-09-16 |
| JP5479332B2 (ja) | 2014-04-23 |
| CN101815793A (zh) | 2010-08-25 |
| WO2008157353A1 (en) | 2008-12-24 |
| EP2171086A4 (en) | 2010-10-13 |
| EP2171086A1 (en) | 2010-04-07 |
| BRPI0813364A2 (pt) | 2014-12-30 |
| MX2009013646A (es) | 2010-03-30 |
| RU2010101093A (ru) | 2011-07-20 |
| EP2171086B1 (en) | 2012-12-19 |
| US20090017012A1 (en) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2690865A1 (en) | Methods of diagnosing and treating cancer | |
| AU2023266384A1 (en) | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations | |
| US7795033B2 (en) | Methods to predict the outcome of treatment with antidepressant medication | |
| Kang et al. | Aberrant allele-switch imprinting of a novel IGF1R intragenic antisense non-coding RNA in breast cancers | |
| Ling et al. | Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer | |
| CN102732600A (zh) | 肿瘤个性化治疗基因测评及套组方法 | |
| Jin et al. | EML4-ALK fusion gene in Korean non-small cell lung cancer | |
| Talbi et al. | Genetic heterogeneity of congenital hearing impairment in Algerians from the Ghardaïa province | |
| Ueda et al. | Glutathione S‐transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells | |
| CN108192974A (zh) | 长链非编码rna linc00842作为生物标志物在制备肺腺癌预后检测制剂中的应用 | |
| EP2370595B1 (en) | Method of stratifying breast cancer patients based on gene expression | |
| Tanuma et al. | FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma | |
| Zhang et al. | Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy | |
| ES2377062T3 (es) | Métodos para determinar un régimen quimioterapéutico basado en la pérdida de heterocigosidad en el locus de timidilato sintasa | |
| CN102676644A (zh) | 前列腺癌发病风险基因评估方法及诊断试剂盒 | |
| CA2479968A1 (en) | Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome | |
| Fernández-Contreras et al. | Combination of polymorphisms within 5'and 3'untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients | |
| Passamonti et al. | Blast phase of essential thrombocythemia: A single center study | |
| Wang et al. | Effects of TERT gene polymorphism and environmental factor interactions on lung cancer risk in the Xi’an Han population | |
| CN112746100A (zh) | 用于kir基因分型的引物、试剂盒及方法 | |
| Gibadulinová et al. | Expression of S100P protein correlates with and contributes to the tumorigenic capacity of HeLa cervical carcinoma cells | |
| JP2024504367A (ja) | がんを治療及び改善するための方法 | |
| Arifin et al. | EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung | |
| Wang et al. | Effects of the ANXA6 polymorphisms on glioma risk and patients prognosis | |
| CN108192975A (zh) | 长链非编码rna linc00559作为生物标志物在制备肺鳞癌预后检测制剂中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130515 |
|
| FZDE | Discontinued |
Effective date: 20160126 |